REBIRTH Mitglieder

Prasse, Antje

Prasse, Antje , Prof. Dr. med.


A. Prasse (*1969), M.D., is head of ILD (Interstitial Lung Disease) clinic and research at Hannover Medical School, division of pulmonology and Attract group leader at ITEM. Re-search of A. Prasse focuses on molecular and cell biology of chronic lung diseases such as pulmonary fibrosis and COPD as well as biomarkers. Her lab established a new 3D-Organoid model for lung remodeling studies and a humanized mouse model for IPF based on patient derived human epithelial progenitor cells. In collaboration with industries she exploits currently several new targets/ compounds for treatment of either pulmonary fibrosis or COPD by preclinical models and early proof of concept studies

Biography / About

Date of Birth:June, 1969
Function:Professor at the Institute of Pneumology, Hannover Medical School (MHH), Head of the Attract research group “Clinical and Translational Fibrosis Research”, ITEM


1988 - 1995Studies of Medicine at the Albert Ludwigs University of Freiburg, Germany
1995 - 2001Internship and Residency, University Medical Center Freiburg, (Prof. Matthys)
2001 - 2013Consultant, Head of outpatient clinic, University Medical Center Freiburg
2005Board Certification Internal Medicine, University Medical Center Freiburg
2008Board Certification Pneumology, University Medical Center Freiburg

Academic appointments and Research posts:

2008Assistant Professor, Albert Ludwigs University of Freiburg
2010Second Appointment, Director of Respiratory Medicine, LMU Munich, Germany
2013Visiting Professorship, Host: Prof. Naftal Kaminski, Yale University, CT, USA
2014Associate Professor, Head of Diffuse Parenchymal Lung Disease (DPLD) clinic, MHH
2014Attract Group Leader, Head of Fibrosis Research, ITEM
2014Principle Investigator (PI), Coordinator DPLD Area, German Network of Lung Research (DZL - BREATH)
2016PI, DFG clinical research unit 311 ‘KFO 311: (pre-) terminal heart and lung failure’

Other professional activities:

Since 2007Collaborative Research Projects with industry (Boehringer Ingelheim, Biogen Idec, Astra-Zeneca, Vertex, Roche, AdAlta, Navitor, Genentech, Sanofi-Aventis)
Since 2011Advisory Board member: Boehringer Ingelheim, Sanofi- Aventis, Roche, Bayer

Awards and Prizes:

2006Science Award of the German Pulmonary Society
2009Research Award of the German Pulmonary Society
2015European Respiratory Society IPF Research Award

Major research interests:

  • Mislead lung remodeling
  • Repair mechanisms in adult airway and parenchymal lung diseases
  • Fibrosis
  • Lung regeneration
  • Epithelial lung progenitor cells

Selected Publications:

  1. Bonella F, Kreuter M, Hagmeyer L, Neurohr C, Keller C, Kohlhaeufl MJ, Müller-Quernheim J, Milger K, Prasse A. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration. 2016. 92:98-106.
  2. Schupp JC, Binder H, Jäger B, Cillis G, Zissel G, Müller-Quernheim J, Prasse A. Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis. PLoS One. 2015. 15;10:e0116775.
  3. Schupp J, Becker M, Günther J, Müller-Quernheim J, Riemekasten G, Prasse A. Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. European Respiratory Journal. 2014. 43(5):1530.
  4. Stahl M, Schupp J, Jäger B, Zissel G, Schmid M, Müller-Quernheim J, Prasse A. Lung Collagens Perpetuate Pulmonary Fibrosis via CD204 and M2 Macrophage Activation. PLoS One. 2013. 8:e81382.
  5. Duque-Afonso J, Ihorst G, Wasch R, Bertz H, Muller-Quernheim J, Finke J, Prasse A, Marks R. Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. Bone Marrow Transplant. 2013. 48(8):1098-103.
  6. Ziegler-Heitbrock L, Frankenberger M, Heimbeck I, Burggraf D, Wjst M, Häussinger K, Brightling C, Gupta S, Parr D, Subramanian D, Singh D, Kolsum U, Boschetto P, Potena A, Gorecka D, Nowinski A, Barta I, Döme B, Strausz J, Greulich T, Vogelmeier C, Bals R, Hohlfeld JM, Welte T, Venge P, Gut I, Boland A, Olaso R, Hager J, Hiemstra P, Rabe KF, Unmüssig M, Müller-Quernheim J, Prasse A. The EvA study: aims and strategy. Eur Respir J. 2012. 40:823-9.
  7. Prasse A, Zissel G, Lützen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, Rensing-Ehl A, Bacher G, Cavalli V, Bevec D, Delgado M, Müller-Quernheim J. Inhaled Vasoactive Intestinal Peptide Exerts Immuno-regulatory Effects in Sarcoidosis. Am J Respir Crit Care Med. 2010. 182: 540-8.
  8. Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, Olschewski M, Rottoli P, Müller-Quernheim J. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009. 179:717-23.
  9. Prasse A, Pechkovsky DV, Toews GB, Schafer M, Eggeling S, Ludwig C, Germann M, Kollert F, Zissel G, Muller-Quernheim J. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum. 2007. 56(5):1685-93.
  10. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Müller-Quernheim J, Zissel G. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006. 173:781-92.

[zurück zur Liste]
Diese Webseite verwendet Cookies und die Webanalyse-Software Google Analytics. Klicken Sie hier für weitere Informationen zum Datenschutz.